Form S-8 Apellis Pharmaceuticals,
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Apellis Pharmaceuticals (APLS) PT Lowered to $75 at Raymond James
March 3, 2025 7:56 AM ESTRaymond James analyst Steven Seedhouse lowered the price target on Apellis Pharmaceuticals (NASDAQ: APLS) to $75.00 (from $78.00) while maintaining a Strong Buy rating.
The analyst comments "We reiterate our Strong Buy rating on APLS following 4Q24 earnings. Given sales were pre-announced during JPM (see our... More
